HRP20210744T1 - Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora - Google Patents
Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora Download PDFInfo
- Publication number
- HRP20210744T1 HRP20210744T1 HRP20210744TT HRP20210744T HRP20210744T1 HR P20210744 T1 HRP20210744 T1 HR P20210744T1 HR P20210744T T HRP20210744T T HR P20210744TT HR P20210744 T HRP20210744 T HR P20210744T HR P20210744 T1 HRP20210744 T1 HR P20210744T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- met
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 108060003951 Immunoglobulin Proteins 0.000 claims 10
- 102000018358 immunoglobulin Human genes 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000004850 protein–protein interaction Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000009161 IPT domains Human genes 0.000 claims 1
- 108050000019 IPT domains Proteins 0.000 claims 1
- 102000009203 Sema domains Human genes 0.000 claims 1
- 108050000099 Sema domains Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 102000057308 human HGF Human genes 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Anti-c-Met protutijelo ili njegov fragment koji veže antigen, pri čemu se protutijelo ili njegov fragment koji veže antigen veže na humani c-MET s afinitetom od najmanje 10-8M, pri čemu je protutijelo protutijelo IgG tipa i pri čemu protutijelo sadrži aminokiselinske sekvence teškog i lakog lanca prema SEQ ID NO:1 i SEQ ID NO: 2, ili SEQ ID NO: 3 i SEQ ID NO: 4, ili SEQ ID NO: 5 i SEQ ID NO: 6, ili SEQ ID NO: 7 i SEQ ID NO: 8.
2. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 1, naznačeno time što se protutijelo ili njegov fragment koji veže antigen veže na humanu c-MET varijantu N375S.
3. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time što se protutijelo ili njegov fragment koji veže antigen veže na epitop koji se nalazi u SEMA domeni humanog c-MET i inhibira c-MET signalizaciju.
4. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1-3, naznačeno time što protutijelo ili njegov fragment koji veže antigen veže na epitop koji se nalazi u IPT domenama 1-4 humanog c-MET i inhibira c-MET signalizaciju.
5. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 3 ili zahtjevu 4, naznačeno time što protutijelo ili njegov fragment koji veže antigen inhibira vezanje rekombinantnog humanog HGF rekombinanta na humani c-MET ECD pri koncentraciji od 0.9x10-9M ili manje za 50% ispitivanju imunosorbentom vezanim za enzim pomoću HGF-a u čvrstoj fazi.
6. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1-5, naznačeno time što je protutijelo ili fragment koji veže antigen Fab.
7. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1-5, naznačeno time što je protutijelo ili fragment koji veže antigen F(ab')2.
8. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1-5, naznačeno time što je protutijelo ili fragment koji veže antigen scFv.
9. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1-8, naznačeno time što je protutijelo ili njegov fragment koji veže antigen dalje spareno s dijagnostičkim ili terapijskim sredstvom.
10. Heterodimerna molekula imunoglobulina koja sadrži
(i) prvi i drugi Fab ili scFv fragment koji se specifično vežu na humani c-MET, i
(ii) zglobnu regiju protutijela, CH2 domenu protutijela i CH3 domenu protutijela koje sadrže hibridnu domenu hibridnu domenu sučelja interakcije protein-protein pri čemu je navedena domena sučelja interakcije nastala aminokiselinskim segmentima CH3 domene prvog člana i aminokiselinskim segmentima CH3 domene navedenog drugog člana, pri čemu je navedena domenu sučelja interakcije protein-protein prvog lanca u interakciji sa sučeljem protein-protein drugog lanca pomoću homodimerizacije odgovarajućih segmenata aminokiselina istog člana super-obitelji imunoglobulina unutar navedenih domena interakcije,
pri čemu prvi konstruirani lanac imunoglobulina ima polipeptidnu sekvencu ("AG-SEED"):
GQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTP SRQEPSQGTT TFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISL i drugi konstruirani lanac imunoglobulina ima polipeptidnu sekvencu ("GA-SEED"):
GQPREPQVYTLPPPSEELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKILT WAPVLDSDG SFFLYSILRVAAEDWKKGDTFSCSVMHEALHNHYTQKSLDR i pri čemu prvi i/ili drugi Fab ili scFv fragment sadrže najmanje dvije sekvence aminokiselina prema SEQ ID NO: 1, SEQ IDNO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8.
11. Heterodimerna molekula imunoglobulina prema patentnom zahtjevu 10, naznačena time što je heterodimerna molekula imunoglobulina dalje sparena s dijagnostičkim ili terapijskim sredstvom.
12. Protutijelo prema patentnom zahtjevu 9, ili heterodimerna molekula imunoglobulina prema patentnom zahtjevu 11, naznačeni time što je terapijsko sredstvo citotoksin.
13. Heterodimerna molekula imunoglobulina prema patentnom zahtjevu 12, naznačena time što je heterodimerna molekula imunoglobulina afukozilirana.
14. Protutijelo prema patentnom zahtjevu 12, ili heterodimerna molekula imunoglobulina prema patentnom zahtjevu 12 ili zahtjevu 13 naznačeni time što su za uporabu u liječenju karcinoma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188857 | 2016-09-14 | ||
| EP17769025.2A EP3512882B1 (en) | 2016-09-14 | 2017-09-14 | Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition |
| PCT/EP2017/073106 WO2018050733A1 (en) | 2016-09-14 | 2017-09-14 | Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210744T1 true HRP20210744T1 (hr) | 2021-06-25 |
Family
ID=56936324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210744TT HRP20210744T1 (hr) | 2016-09-14 | 2021-05-12 | Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190248907A1 (hr) |
| EP (1) | EP3512882B1 (hr) |
| JP (1) | JP2020500835A (hr) |
| CN (1) | CN109937211A (hr) |
| AU (1) | AU2017327658A1 (hr) |
| CA (1) | CA3036596A1 (hr) |
| DK (1) | DK3512882T3 (hr) |
| ES (1) | ES2876151T3 (hr) |
| HR (1) | HRP20210744T1 (hr) |
| HU (1) | HUE054571T2 (hr) |
| IL (1) | IL265362B2 (hr) |
| LT (1) | LT3512882T (hr) |
| PL (1) | PL3512882T3 (hr) |
| PT (1) | PT3512882T (hr) |
| RS (1) | RS61932B1 (hr) |
| SI (1) | SI3512882T1 (hr) |
| WO (1) | WO2018050733A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US20210163604A1 (en) * | 2018-03-28 | 2021-06-03 | Mitsubishi Tanabe Pharma Corporation | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
| JOP20210233A1 (ar) | 2019-02-26 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met. |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| CA3146933A1 (en) | 2019-09-16 | 2021-03-25 | Marcus KELLY | Radiolabeled met binding proteins for immuno-pet imaging |
| CN112552404B (zh) * | 2020-07-20 | 2022-02-08 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
| JP2024515266A (ja) * | 2021-04-08 | 2024-04-08 | ビョンディス・ビー．ブイ． | 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体 |
| WO2024030341A1 (en) | 2022-07-30 | 2024-02-08 | Pinetree Therapeutics, Inc. | Compositions for targeted lysosomal degradaton and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
| US20100062441A1 (en) * | 2007-03-15 | 2010-03-11 | Ravi Salgia | C-met mutations and uses thereof |
| EP2435053B1 (en) | 2009-05-28 | 2018-11-14 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EP2928503B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugates of auristatin compounds |
| US9631218B2 (en) | 2013-03-15 | 2017-04-25 | The Trustees Of The University Of Pennsylvania | Sortase-mediated protein purification and ligation |
| EP3909984A1 (en) * | 2015-11-03 | 2021-11-17 | Merck Patent GmbH | Affinity matured c-met antibodies |
-
2017
- 2017-09-14 WO PCT/EP2017/073106 patent/WO2018050733A1/en unknown
- 2017-09-14 JP JP2019514225A patent/JP2020500835A/ja not_active Ceased
- 2017-09-14 PL PL17769025T patent/PL3512882T3/pl unknown
- 2017-09-14 LT LTEP17769025.2T patent/LT3512882T/lt unknown
- 2017-09-14 IL IL265362A patent/IL265362B2/en unknown
- 2017-09-14 DK DK17769025.2T patent/DK3512882T3/da active
- 2017-09-14 RS RS20210710A patent/RS61932B1/sr unknown
- 2017-09-14 ES ES17769025T patent/ES2876151T3/es active Active
- 2017-09-14 SI SI201730794T patent/SI3512882T1/sl unknown
- 2017-09-14 CA CA3036596A patent/CA3036596A1/en active Pending
- 2017-09-14 AU AU2017327658A patent/AU2017327658A1/en active Pending
- 2017-09-14 HU HUE17769025A patent/HUE054571T2/hu unknown
- 2017-09-14 EP EP17769025.2A patent/EP3512882B1/en active Active
- 2017-09-14 CN CN201780070335.2A patent/CN109937211A/zh active Pending
- 2017-09-14 PT PT177690252T patent/PT3512882T/pt unknown
- 2017-09-14 US US16/333,436 patent/US20190248907A1/en not_active Abandoned
-
2021
- 2021-05-12 HR HRP20210744TT patent/HRP20210744T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL265362B2 (en) | 2024-05-01 |
| IL265362A (en) | 2019-05-30 |
| WO2018050733A1 (en) | 2018-03-22 |
| ES2876151T3 (es) | 2021-11-12 |
| EP3512882B1 (en) | 2021-03-10 |
| EP3512882A1 (en) | 2019-07-24 |
| AU2017327658A1 (en) | 2019-05-02 |
| IL265362B1 (en) | 2024-01-01 |
| LT3512882T (lt) | 2021-06-25 |
| PT3512882T (pt) | 2021-06-14 |
| CA3036596A1 (en) | 2018-03-22 |
| PL3512882T3 (pl) | 2022-01-10 |
| CN109937211A (zh) | 2019-06-25 |
| RS61932B1 (sr) | 2021-07-30 |
| DK3512882T3 (da) | 2021-05-31 |
| SI3512882T1 (sl) | 2021-08-31 |
| HUE054571T2 (hu) | 2021-09-28 |
| JP2020500835A (ja) | 2020-01-16 |
| US20190248907A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210744T1 (hr) | Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora | |
| JP2020063262A5 (hr) | ||
| EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
| JP2022177090A5 (hr) | ||
| EA201200526A1 (ru) | Поливалентные антитела, стабилизированные дисульфидом | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| BRPI0715660B8 (pt) | anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal | |
| JP2018512175A5 (hr) | ||
| HRP20161449T1 (hr) | Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena | |
| JP2019502405A5 (hr) | ||
| JP2020058359A5 (hr) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| EA201100527A1 (ru) | Биологические продукты | |
| JP2020530272A5 (hr) | ||
| HRP20090324T1 (hr) | Moduliranje interakcije između hgf beta lanca i c-met | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
| JP2013502445A (ja) | 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物 | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| BR112021017399A2 (pt) | Proteína de fusão bifuncional e uso farmacêutico da mesma | |
| JP2011526249A5 (hr) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
| JP2016531546A5 (hr) |